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Introduction: Despite similar clinical and pathological features, large numbers of breast cancer patients experience
different outcomes of the disease. This, together with the fact that the incidence of breast cancer is growing
worldwide, emphasizes an urgent need for identification of new biomarkers for early cancer detection and
stratification of patients.
Methods: We used ultrahigh-resolution microarrays to compare genomewide methylation patterns of breast carcinomas
(n = 20) and nonmalignant breast tissue (n = 5). Biomarker properties of a subset of discovered differentially methylated
regions (DMRs) were validated using methylation-sensitive high-resolution melting (MS-HRM) in a case–control study on
a panel of breast carcinomas (n = 275) and non-malignant controls (n = 74).
Results: On the basis of microarray results, we selected 19 DMRs for large-scale screening of cases and controls. Analysis
of the screening results showed that all DMRs tested displayed significant gains of methylation in the cancer
tissue compared to the levels in control tissue. Interestingly, we observed two types of locus-specific methylation, with
loci undergoing either predominantly full or heterogeneous methylation during carcinogenesis. Almost all tested DMRs
(17 of 19) displayed low-level methylation in nonmalignant breast tissue, independently of locus-specific methylation
patterns in cases.
Conclusions: Specific loci can undergo either heterogeneous or full methylation during carcinogenesis, and loci
hypermethylated in cancer frequently show low-level methylation in nonmalignant tissue.Introduction
Denmark has the highest standardized incidence of
breast cancer in the world, with over 4,500 new cases
annually [1]. The breast cancer incidence has increased
since the mid-1980s, and, despite the fact that early de-
tection combined with specialized treatment has signifi-
cantly improved the survival of cancer patients, the
disease still presents a problem for healthcare systems.* Correspondence: wojdacz@hum-gen.au.dk
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reproduction in any medium, provided the orBreast cancer treatment, as well as treatment of any
other cancer, can be approached at two levels: first, early
detection, which is critical for long-term survival of the
patients, and second, personalized patient care, which
potentially can become the most successful approach in
cancer treatment. Both of these approaches require bio-
markers for patient identification and stratification.
Methylation is a well-established epigenetic process of
gene expression regulation. In general terms, methyla-
tion of promoter sequences of protein-coding genes re-
sults in transcriptional downregulation of the gene, and
hypomethylation of previously methylated promoter re-
gions permits transcription [2]. Two adverse phenomena
characterize the process of carcinogenesis: locus-specificl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from cancer genomes. Hypermethylation of promoters
has been widely shown to contribute to silencing of
tumor suppressor genes during carcinogenesis. Global
hypomethylation of the cancer genome was initially
shown to cause genomewide allelic instability, but re-
cently the involvement of this process in transcriptional
gene regulation has become increasingly recognized [2].
DNA methylation changes have been shown to take part
in the very first steps of neoplastic transformation,
which makes methylation biomarkers very attractive
targets for early cancer detection [3]. Moreover, many
phenotypical features of the cancer are a consequence
of the methylation changes. Those changes are pre-
dominantly cancer type–specific and therefore have
potential to be powerful biomarkers for cancer patient
stratification [4].
In general, clinically useful biomarkers must be applic-
able in one of the clinical disease management areas:
diagnostics, prognostication and treatment monitoring.
More than three decades of epigenetic research have
provided strong research evidence that methylation-
based biomarkers can be applied in all the above areas
of clinical use. Nevertheless, current use of methylation
biomarkers in clinical cancer management is very lim-
ited. The difficulties in clinical implementation of the
methylation biomarkers can be attributed mainly to low
number of studies focused on extensive clinical valid-
ation of the novel (and known) biomarkers.
A study aiming to develop a methylation biomarker
for clinical use should, apart from utilizing state-of-the-
art methylation detection methodologies, consist of five
steps:
1. Discovery, whereby, in most of the cases
genomewide screening is applied in a search for the
candidate biomarkers;
2. Initial clinical validation, whereby each candidate
biomarker must be shown to provide an ability to
distinguish nonmalignant healthy tissue from
malignant cancer tissue;
3. Retrospective validation, whereby archival material
is used to determine if there is a significant
correlation between specific methylation changes
and the disease phenotype. (Detailed records
accompanying patient samples are critical for this
part of the biomarker development process, and it is
highly advisable to use samples from various patient
populations in these studies.);
4. Prospective validation, whereby the biomarker is
used in clinical trials; and
5. Long-term monitoring of the biomarker’s clinical use
after the above-described biomarker development
process to assess its impact.Herein we present and discuss the results of the first
two stages of the proposed biomarker development
process for breast cancer.
Methods
Clinical sample material
Twenty freshly frozen breast carcinomas were obtained
from Aarhus University Hospital, and DNA was ex-
tracted from those samples using the DNeasy Blood &
Tissue Kit (QIAGEN, Hilden, Germany) according to
the manufacturer’s protocol. Seventy-four nonmalignant
breast tissue samples from breast reduction surgeries
were collected at the Department of Plastic Surgery,
Aarhus University Hospital. The women undergoing
breast reduction surgery had had mammograms, and
only women without signs of malignancies were enrolled
in this study. The breast tissue obtained from breast re-
ductions can potentially differ from healthy breast tissue;
however, because of ethical considerations, this type of
control material was the only available source for our
experiments. DNA taken from breast reduction samples
was also extracted using the DNeasy Blood & Tissue Kit.
Tumor DNA for screening analyses was obtained from
274 patients diagnosed with sporadic breast cancer. The
DNA samples were collected between 1992 and 1994 at
Aarhus University Hospital. Complete information about
the breast cancer cohort and DNA extraction procedure
were previously published [5,6]. Patient consent for our
use of the human material in this study was obtained
and approved by the Research Ethics Committee of Mid
Jutland, Denmark.
Microarray analyses
DNA for microarray experiments was extracted from 20
freshly frozen tumor tissue samples. After extraction,
the methylated DNA fragments were enriched in each
sample using a methylated DNA immunoprecipitation
(MeDIP) protocol. A detailed description of the proced-
ure can be found in Additional file 1. The same proced-
ure was applied for five tissue samples taken from
women who had undergone breast reduction surgery,
and these served as a control for the microarray experi-
ments. Two fractions from each sample (MeDIP enriched
and input) were labeled with Cy5 and Cy3, respectively,
and cohybridized to the NimbleGen Human DNA Methy-
lation 2.1M Deluxe Promoter Array (Roche/NimbleGen,
Madison, WI, USA). Arrays were processed using Nimble-
Scan software (Roche/NimbleGen) to produce log2 signal
ratios at each probe. These ratios were averaged within
each class of sample to produce a single set of mean ratios
per class. The mean ratio sets were processed again with
NimbleScan software to generate a relative enrichment
score at each probe for each class using a Kolmogorov-
Smirnov test in a window (750 bp) around each probe.
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were subtracted to produce a differential score indicating
enrichment or depletion of signal in one group relative to
the other, and a significance threshold of 2 was applied to
the differential scores. Two or more consecutive signifi-
cant differential scores within 500 bases of each other con-
stituted a differentially methylated region (DMR). Each
DMR was mapped to the genome using NimbleScan soft-
ware. Lists of the annotated regions can be found in Add-
itional file 2. For the results presented in this paper, only
the list of DMRs computed by subtraction of tumors from
controls (hypermethylated DMRs) was manually mined
for the candidate biomarkers. The potential candidate bio-
markers (total of 24) with the highest differential scores
were selected for validation analyses. All validation experi-
ments were performed using methylation-sensitive high-
resolution melting (MS-HRM) and verified by Sanger se-
quencing. The microarray data were deposited in the
Gene Expression Omnibus database (GEO) database
[GEO:GSE43095].
Methylation-sensitive high-resolution melting
All MS-HRM assays were designed according to previ-
ously published guidelines and optimized to allow for
highly sensitive methylation detection [7,8]. In each run,
a range of standards was included to control for un-
biased sensitivity of the detection: 0% (unmethylated:
EpiTect Control DNA; QIAGEN), 1% and 10% (fully
methylated template in an unmethylated background)
and 100% (methylated: EpiTect Control DNA). MS-
HRM amplification was performed in triplicates. PCR
mix consisted of 1× LightCycler 480 High Resolution
Master mix (Roche, Penzberg, Germany), 3 mM Mg2+,
250 to 500 nM concentrations of each primer and 6 ng
of template. PCR amplifications and HRM analyses were
performed on the LightCycler 480 platform (Roche) and
included 50 cycles at the assay-specific parameters de-
scribed in Additional file 3. The conditions and primer
sequences used in MS-HRM experiments are listed in
Additional file 3. Bisulfite conversions of the clinical
samples were performed with the EZ DNA Methylation-
Gold Kit (ZymoResearch, Irvine, CA, USA).
Sequencing analyses
To confirm the MS-HRM results, a subset of MS-HRM
PCR products was sequenced using the Sanger method
as previously described [9]. In brief, PCR products ob-
tained from MS-HRM analyses were directly sequenced
using the same primers as those used for the MS-HRM
analyses. To decrease the costs and labor required for
the sequencing, the forward strand was sequenced from
all the representative samples. In cases of ambiguous re-
sults, the reverse strand was also sequenced. Overall, we
performed more than 300 sequencing reactions to confirmthe MS-HRM results. Despite the fact that we attempted
to sequence very small PCR products (around 100 bp; for
details, see Additional file 3), we successfully and reprodu-
cibly confirmed the methylation status for each HRM pro-
file group described herein (see Results). We were not able
to sequence WT1 and SIX6 PCR products (a very short
PCR product), but our high confidence in the sequencing
data derived from all other assays allowed us to generalize
the results for those two DMRs. The sequencing data for
samples displaying low-level methylation for the HTR1B
MS-HRM assay did not show methylation. However taking
into account both superior sensitivity of the MS-HRM over
sequencing [9] and the fact that all other low-methylation
profiles showed methylation on the sequencing data, we
have classified these samples as low-level methylated
(Table 1).
Statistical analyses
The statistical analyses were performed with the Stata
10.1 software package (StataCorp, College Station, TX,
USA) and R statistics.
Results
Identification of hypermethylated loci
In the first part of this study, we focused on identifica-
tion of hypermethylated DMRs in breast cancer. Nim-
bleScan mapping of DMRs extracted from array data
showed that DMRs detected in our sample panel could
potentially be associated with more than 1,000 func-
tional genomic elements (see Additional file 2 for a
complete list and coordinates of the DMRs). A direct in-
dication of the accuracy of this part of our experimental
approach was the finding that loci previously reported to
undergo hypermethylation during breast cancer patho-
genesis, such as for example PAX2, MYOD1 and PITX2,
were also detected in our microarray experiments. For
each called DMR, our microarray data analysis workflow
(see Methods) provided us with a differential score. This
value is in principle a derivative of the methylation dif-
ference between cases and controls. We observed that
the higher the score, the more pronounced the methyla-
tion gain, when we compared both cases and controls.
Therefore, 23 DMRs with the highest differential score
were selected for the MS-HRM-based microarray valid-
ation experiments. MS-HRM assays were targeted to the
called DMR or to the closest region that potentially
could undergo differential methylation (for example, a
CpG island (CGI)). The results of the MS-HRM micro-
array validation corroborated the microarray results for
21 of the selected target sequences (unpublished data
[7]). At this point in our experimental procedure, the
MS-HRM results indicated low-level methylation in the
control samples for a subset of the assays. However, the
methylation level of those loci was significantly higher in














TITF1 220 0 (0.0) 38 (17.3) 0 145 (65.9) 37 (16.8)
HOXB13 239 18 (7.5) 20 (8.4) 0 23 (9.6) 178 (74.5)
NR2E1 164 15 (9.1) 14 (8.5) 18 (11.0) 89 (54.3) 28 (17.1)
HTR1B 162 28 (17.3) 68 (42.0) 20 (12.3) 4 (2.5) 42 (25.9)
HMX2 187 9 (4.8) 1 (0.5) 13 (7.0) 164 (87.7) 0
BC008699 261 4 (1.5) 4 (1.5) 26 (10.0) 206 (78.9) 21 (8.0)
SLC38A4 234 0 16 (6.8) 93 (39.7) 80 (34.2) 45 (19.2)
FLJ32447 264 0 28 (10.6) 191 (72.3) 48 (18.2) 0
WT1 218 44 (20.2) 0 178 (81.7) 21 (9.6) 0
TMEM132D 218 6 (2.8) 21 (9.6) 154 (70.6) 16 (7.3) 21 (9.6)
NKX2-3 169 0 16 (9.5) 108 (63.9) 38 (22.5) 7 (4.1)
GHSR 260 56 (21.5) 24 (9.2) 180 (69.2) 0 0
ONECUT 243 0 16 (9.5) 134 (55.1) 63 (25.9) 30 (12.3)
LHX1 243 0 28 (11.5) 145 (59.7) 41 (16.9) 29 (11.9)
SIX6 246 5 (2.0) 11 (4.5) 173 (70.3) 55 (22.4) 2 (0.8)
CA10 230 21 (9.1) 48 (20.9) 137 (59.6) 24 (10.4) 0
CHR 252 0 44 (17.5) 192 (76.2) 16 (6.3) 0
POU4F 255 10 (3.9) 6 (2.4) 195 (76.5) 44 (17.3) 0
PHOX2B 256 0 3 (1.2) 199 (77.7) 53 (20.7) 1 (0.4)
aVariable numbers of the samples are reported because of clinical sample limitations. bLow methylation is referred to as methylation similar to the methylation
observed in control samples.
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this experiment was therefore critical [7,10]. At the same
time, this finding indicates that the microarray used in
our experiments is able to robustly detect small relative
differences in methylation between cases and controls.
Two of the MS-HRM assays used in the microarray
validation experiments did not confirm the microarray
results. One possible explanation is that PCR-based MS-
HRM assays cover only approximately 100 bp, whereas
the region with aberrant methylation called on the
microarray can span large genomic regions and the
methylation status within those sequence can differ [11].
Design of PCR assays without prior knowledge of the
methylation changes throughout the region is still
challenging and can simply result in targeting the part
of the regions that does not undergo cancer-dependent
methylation changes. This explanation does not rule
out the possible technological limitations of the micro-
array technology, however, which can lead to false dis-
coveries. Despite the fact that false-positive results
were present at a very low rate in our data set, the fact
that they were present at all underlines the critical im-
portance of validation of the results obtained by any
genomewide screening technology by using PCR-based
methods.Initial clinical validation
All DMRs positively validated in the microarray valid-
ation experiments were subjected to initial clinical valid-
ation screening. In principle, this part of the biomarker
development workflow aims to show (with a statistically
sound sample number) the potential of the discovered
DMR to distinguish between cancer (cases) and healthy
controls. We have screened 275 samples of breast cancer
with the same MS-HRM assays used in the microarray
validation process as well as 74 DNA samples from
breast reduction surgeries (representing healthy con-
trols). The overall results of the initial clinical validation
screening for the 19 DMRs are presented in Tables 1
and 2. The results of the screening for three of the
DMRs are not included in the tables because the MS-
HRM data for those DMRs were challenging to inter-
pret. Further analyses of those loci have to be performed
to clarify whether those DMRs are affected by specific
genetic events occurring during breast tumor carcino-
genesis (data not shown). The samples from the control
group were subclassified into three groups on the basis
of the MS-HRM results (Table 2): (1) samples displaying
no methylation; (2) samples showing low levels of methy-
lation with low-level methylation defined as methylation
less than 1% standard or any aberrations from the
Table 2 Frequencies of DNA methylation in control tissue samples







TITF1 72 47 (65.3) 25 (34.7) 0
HOXB13 72 13 (18.1) 59 (81.9) 0
NR2E1 72 6 (8.3) 66 (91.7) 0
HTR1B 69 0 69 (100.0) 0
HMX2 69 45d (65.2) 24 (34.8) 0
BC008699 72 21 (29.2) 48 (66.7) 3 (4.2)
SLC38A4 62 30 (48.4) 29 (46.8) 3 (4.8)
FLJ32447 70 48 (68.6) 22 (31.4) 0
WT1 72 2 (2.8) 70 (97.2) 0
TMEM132D 70 37 (52.9) 33 (47.1) 0
NKX2-3 68 68 (100.0) 0 0
GHSR 72 2 (2.8) 70 (97.2) 0
ONECUT 71 24 (33.8) 47 (66.2) 0
LHX1 72 0 54 (75.0) 18 (25.0)
SIX6 69 8 (11.6) 61 (88.4) 0
CA10 47 24 (51.1) 23 (48.9) 0
CHR 72 72 (100.0) 0 0
POU4F 37 11 (29.7) 26 (70.3) 0
PHOX2B 72 72 (100.0) 0 0
aVariable number of samples is reported due to clinical sample limitations. bLow methylation is referred to as methylation similar to the methylation level
observed in the 1% methylation standard. cMethylation-positive samples are referred to as samples displaying a HRM profile characteristic for cases. dMethylation
level similar to the one observed in the 1% to 10% methylation standard.
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ples. Interestingly, the cancer samples displayed a sig-
nificant variety of the HRM profiles. The MS-HRM
technology allowed us to evaluate heterogeneous methyla-
tion in each sample screened. Heterogeneous methylation
is referred to as the presence in the sample of multiple
epialleles, each with a different pattern of methylated and
unmethylated CpG sites for a given region. Heteroge-
neously methylated samples display a characteristic HRM
profile for the complex mixture of heteroduplexes formed
between strands that only differ at a few CpG sites. The
evaluation of heterogeneous methylation was not previ-
ously performed on a large scale owing to technological
limitations of the methods for methylation screening.
The significance of heterogeneous methylation is still
debated, but this phenomenon may potentially be critical
for the clinical application of methylation biomarkers
(see Discussion for more details). Therefore, we have
chosen to subdivide our results into five groups (see
Table 1): (1) methylation-positive samples, (2) methylation-
negative samples, (3) samples displaying heterogeneous
methylation pattern, samples showing only fully methyl-
ated melting profiles and (5) samples with both methylated
and unmethylated alleles present. Figure 1 illustrates exam-
ples of the different classes of HRM profiles detected in
our analyses. To confirm the accuracy of the classificationof HRM profiles, we performed sequencing of a subset of
the samples from each of the HRM profile groups and for
each of the DMRs.
Specificity of the biomarkers and low-level methylation
in controls
The specificity of each of DMR was evaluated on the
basis of MS-HRM screening of the control tissue. The
results are presented in Table 2. Interestingly, we ob-
served low-level methylation in control samples for 17
DMRs. The frequency of low-level methylation was as
high as 100% for three of the loci (NKX2-3, CHR and
PHOX2B). In addition, three loci (BC008699, SLC38A4
and LHX1) showed low frequencies of the methylation
levels, similar to those observed in cancer tissue. These
loci will not be further considered for biomarker devel-
opment, as their specificity most likely will be very low.
Figure 2 illustrates examples of the MS-HRM scans with
low methylation levels and verification of the results by
sequencing. Overall, on the basis of the sequencing re-
sults, we conclude that any aberration of the HRM pro-
file from the unmethylated standard indicates the
presence of methylation in the analyzed sample. Only
one DMR in our panel (HMX2) showed methylation
levels between 1% and 10% in the control tissue samples.
The methylation levels in controls at all other DMRs
Figure 1 Examples of the classes of methylation-sensitive high-resolution melting profiles observed in the case sample material.
Standards: 100% methylated (red), 10% methylated in a background of unmethylated template (blue), 1% methylated (yellow) and unmethylated
(green). Sample with a representative methylation-sensitive high-resolution melting profile is shown in black. Melting peaks were generated by
taking the negative derivative (d) of the melting curve data divided by the derivative with respect to time −(d/dT). (A) Fully methylated sample
(BC008699 assay) (B) Sample displaying the presence of both methylated and unmethylated alleles (HOXB13 assay). (C) Heterogeneously
methylated sample (SIX6 assay). (D) Sample with no signs of methylation (CA10 assay).
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against the 1% methylation level standard. The high fre-
quency of low levels of methylation in the control tissue
hampers the specificity of the biomarkers. However, the
quantitative aspect of the MS-HRM technology allows
establishment of a cutoff point for low-level methylation.
High methylation levels in cancer samples
Despite the fact that 17 of the DMRs from our panel
showed low levels of methylation in the control tissue,
those levels seem to be insignificant compared to the
levels of the methylation observed at the same locus in
the cancer samples. All tested DMRs showed drastic
gains of methylation during carcinogenesis. A general
switch in methylation pattern from unmethylated in
controls to methylated in cancer samples for two of the
screened loci (SIX6 and BC008699) is illustrated in
Figure 3. Very few cancer samples in our cohort dis-
played low methylation levels similar to those ob-
served in the control tissue (see Table 1 for details).
For specificity calculations, methylation in those sam-
ples can be interpreted as a normal methylation level
when a cutoff point has been established based on
analyses of methylation in the control group. The cut-
off points for low levels of methylation can provide100% specificity for the methylation biomarkers. How-
ever, before a cutoff point can be established, the
pathological significance of low levels of methylation
within each DMR has to be evaluated.
Two types of locus-specific methylation
The frequencies of methylation in cancer tissue samples
are listed in Table 1. As shown, 12 DMRs in our panel
displayed predominant gains of heterogeneous methyla-
tion affecting from 55% to 81% of the samples. Five of
the DMRs showed very low frequencies of heteroge-
neous methylation (for example, TITF1 and HMX2 with
65% and 87% of the cancer samples, respectively, show-
ing the presence of full methylation of both alleles). No
heterogeneous methylation was seen for the HOXB13
assay, but 74.5% of samples contained both methylated
and unmethylated alleles at this DMR. Only one of the
DMRs screened (SLC38A4) showed balanced frequencies
of heterogeneous and full methylation of 39% and 34%,
respectively.
Functional and clinical effects of hypermethylation of
the DMRs from our panel are outside the scope of this
paper and will be addressed in future projects. However,
it is interesting that the CGI we have targeted with our
HOXB13 assay has previously been shown to undergo
Figure 2 Example of low-level methylation sample at HOXB13 differentially methylated region. Standards: 100% methylated (red), 10%
methylated in a background of unmethylated template (blue), 1% methylated (yellow) and unmethylated standard (green). Sample with a
representative high-resolution melting (HRM) profile (black). The top panel illustrates how even small aberrations of the HRM profile from the
unmethylated standard represent low methylation levels. Methylation-sensitive HRM (MS-HRM) results are shown with the sample in black and
confirmation of the HRM results with sequencing where asterisks indicate double-sequences at CpG sites (both alleles present: T (unmethylated
allele) and C (methylated allele)). Lower panel displays the same data for an unmethylated sample. Melting peaks were generated by taking the
negative derivative (d) of the melting curve data divided by the derivative with respect to time −(d/dT).
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and methylation-dependent expression of the HOXB13
gene has been shown in cancer [13,14]. However, muta-
tions within the HOXB13 gene and the linkage analyses ofthe neighboring 17q21–22 region found this region to be
involved in the development of different cancers [15,16].
Our findings support those observations, and the fact that
our results seem to indicate deactivation of only one allele
Figure 3 Examples of the overall methylation screening results in cases and controls illustrating a shift in methylation of the locus
during carcinogenesis. Standards: 100% methylated (red), 10% methylated in a background of unmethylated template (blue), 1%
methylated (yellow) and unmethylated standard (green). Melting peaks were generated by taking the negative derivative (d) of the melting
curve data divided by the derivative with respect to time −(d/dT). Each panel displays 20 methylation-sensitive high-resolution melting
scans. (A) and (B) BC008699 assay. (C) and (D) SIX6 assay. Scans from control samples are shown in (A) and (C). (B) and (D) show HRM scans
of the cancer tissue samples.
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intriguing.
Overall, our methylation screening results clearly show
that a locus can undergo two types of methylation dur-
ing carcinogenesis: either heterogeneous or full methyla-
tion (at one or both alleles). The type of aberrant
methylation seems to be locus-specific, and the mechan-
ism of this process is unknown. To the best of our
knowledge, our present study is the first to show this
phenomenon, and the physiological and clinical conse-
quences of this process have to be further researched. At
the same time, the high locus specificity of the observed
methylation changes indicates that our results are not a
technological artefact of the methodology used in this
study, but instead reflect a biological phenomenon.
Discussion
There is a strong base of research evidence to support
the utility of methylation biomarkers in the entire
process of clinical disease management, from screening
for predisposition through detection of the condition to
personalized treatment of the disease.
As mentioned in the Introduction, the process of bio-
marker development for clinical applications can be de-
scribed in five steps. The data presented herein addressthe challenges of the first two steps of methylation bio-
marker development for clinical use: discovery and ini-
tial clinical validation. In the biomarker discovery step,
microarray technologies and next-generation sequen-
cing) are indispensable tools affording researchers, in a
single experiment, the ability to uncover a landscape of
methylation changes throughout a cell genome. Cur-
rently, however, the complexity of those technologies
does not allow for straightforward interpretation of the
genomewide screening results. The validation step is es-
pecially important when complicated statistical modeling
is used to process microarray data. In the present study,
we used a very simple statistical model for microarray
data processing (see Methods). Despite the simple ap-
proach involving very little data processing, validation
experiments were necessary. They confirmed low (but
present) false discovery results from the genomewide
screening. This exemplifies the importance of validation
of any genomewide methylation-based study before any
conclusions are drawn. At the same time, our results il-
lustrate that simple statistical models can be very effect-
ive in the discovery of disease-dependent methylation
aberrations.
We have implemented an initial clinical validation of
the biomarkers as a second step in the biomarker
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aimed to answer only the question whether a potential
biomarker can distinguish healthy tissue from cancer tis-
sue, allowed us to address two important, recently emer-
ging questions in the methylation biomarker field: (1)
the question of the prevalence of low-level methylation
of potential biomarkers in healthy tissue and the conse-
quences of this phenomenon for biomarker specificity
and (2) the question of the significance of the evaluation
of heterogeneous methylation of potential biomarkers.
The significance of interindividual differences in low-
level methylation of specific loci is frequently discussed in
the field of methylation biomarkers [17,18]. There is no
consensus with regard to the origin of this phenomenon
and its pathological significance; however, the potential in-
volvement of this type of methylation in disease predis-
position has already been shown [19]. This phenomenon
has direct influence on the specificity of the methylation
biomarkers because, from the biomarker development
perspective, methylation in healthy tissue should not be
present in order for the biomarker to be highly inform-
ative. Our data show that low-level methylation is very fre-
quently present in healthy tissue, and our sequencing
experiments provide evidence that the low-level methyla-
tion we observed in our controls is not a technological
artefact. The quantitative properties of the MS-HRM
technology allow definition of a cut-off point for the low
levels of methylation; however, before that can be done,
the pathological insignificance of the low levels methyla-
tion has to be shown for each biomarker. The high preva-
lence of low-level methylation demonstrated in this study
underlines the notion that evaluation of the low-level
methylation in healthy tissue is critical for biomarker de-
velopment and that only methods that allow for a defin-
ition of a cutoff for background methylation levels are
most likely to be applicable in clinical methylation bio-
marker testing.
As mentioned above, a second very interesting finding
of our initial clinical biomarker validation experiments
in a relatively large-scale study is that the frequency of
heterogeneous methylation can be very high, with some
loci undergoing only heterogeneous methylation during
carcinogenesis. Heterogeneous methylation was previ-
ously shown to occur at some loci, but this phenomenon
has never been studied extensively in a large sample.
One reason could be the technological limitations of
some of the methodologies used for DNA methylation
assessment [9,20,21]. The MS-HRM technology allowed
us to perform methylation screening with the capability
of evaluating heterogeneous methylation in a large sam-
ple panel [9]. To the best of our knowledge, we show for
the first time a trend for loci to undergo two types
of methylation during carcinogenesis, with some loci
undergoing full methylation and others heterogeneousmethylation. Moreover, our results show that heteroge-
neous methylation seems to be as specific to the locus as
full methylation. Full methylation of the locus normally
abolishes transcription. Heterogeneous methylation may
not be sufficient to abolish transcription of the gene, but
may interfere with only the transcription process or may
be a “passenger” of the carcinogenesis process. Never-
theless, these comments are only speculative, and the
physiological and clinical significance of heterogeneous
methylation has to be further researched in the future.
Overall, the initial clinical validation step in our bio-
marker development procedure has allowed us to answer
two critical questions for the potential applicability of
the biomarker in clinical practice; hence, in our opinion,
this step is essential for fast streamlining of the bio-
marker validation process.
Conclusions
Our results show that loci undergoing hypermethylation
during carcinogenesis can acquire either heterogeneous
or full methylation. Furthermore, low-level methylation
at those loci in nonmalignant tissue can be a common
event. Consequently, researchers in studies addressing
the clinical applicability of hypermethylated loci as bio-
markers should evaluate the clinical relevance of both
specific types of methylation, as well as low-level methy-
lation of those loci in nonmalignant tissue.
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